An oral pill for COVID19? Molnupiravir shows promise

After more than one year into the coronavirus disease (COVID-19) pandemic, international vaccination efforts are moving closer to bringing this pandemic to an end. Though several drugs have been repurposed to help patients with COVID-19, scientists are still looking to discover antivirals that are effective against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for COVID-19.

Recently, researchers at the University of North Carolina at Chapel Hill reported molnupiravir as the first oral and direct-acting antiviral that is highly effective at reducing nasopharyngeal SARS-CoV-2 infectious virus and viral ribonucleic acid (RNA) levels.

The study, which appeared in the pre-print server medRxiv*, demonstrates that molnupiravir has favorable safety and tolerability profiles, thus making it a promising antiviral against SARS-CoV-2.

Study: Molnupiravir, an Oral Antiviral Treatment for COVID-19. Image Credit: PHOTOCREO Michal Bednarek / Shutterstock.com

SARS-CoV-2 infection

As of June 25, 2021, SARS-CoV-2 has infected over 180 million people and led to the deaths of 3.9 million deaths globally. SARS-CoV-2 infection can lead to severe symptoms in vulnerable individuals, such as the elderly and those with comorbidities.

Several studies have confirmed the link between high SARS-CoV-2 nasopharyngeal RNA levels and hospitalization rates. Similarly, animal studies have also demonstrated the association between viral RNA levels and transmission rates.

To date, there are no treatments that are currently available to eradicate this infectious virus and prevent its transmission to others. Scientists are therefore racing to find an effective drug, like an oral antiviral, to reduce disease progression and avoid transmission.

First oral and direct-acting antiviral

Molnupiravir is an experimental antiviral drug that is orally active and was originally developed for the treatment of influenza. Merck, known as MSD, developed molnupiravir in collaboration with Ridgeback Biotherapeutics. The drug is now being evaluated in Phase III clinical trial, the MOVe-OUT study, to treat non-hospitalized patients with laboratory-confirmed COVID-19.

Preclinical studies have revealed broad-spectrum antiviral activity of molnupiravir against several coronaviruses, including SARS-CoV-2. In humanized mouse models, the use of molnupiravir as both a treatment and prophylaxis was found to reduce viral replication and pathogenesis.

The current study was based on the results of a Phase IIa trial evaluating the safety, tolerability, and antiviral efficacy of molnupiravir when used to treat COVID-19.

The team included outpatients with confirmed SARS-CoV-2 infection and symptom onset within seven days. Study participants were randomly selected to either receive 1:1 to 200 mg molnupiravir or matching placebo, or 3:1 to molnupiravir (400 or 800 mg) or placebo. The participants received the drug orally twice daily for five days, with dose escalations being allowed after safety data from the current and other studies were completed.

Overall, 202 individuals were included in the study and received at least one dose of molnupiravir or placebo between June 19, 2020, and January 25, 2021, at ten sites in the United States. Of these, seven patients stopped participating in the trial due to adverse effects and participant withdrawal.

The team isolated infectious viruses from 43.5% of nasopharyngeal swabs at baseline. On the third day, isolated infections decreased to 1.9% in patients who received the 800 mg dose molnupiravir, which was comparable to 16.7% of participants who were given the placebo.

Further, infectious virus isolation also decreased on the fifth day in patients given 400 or 800 mg molnupiravir. No patients in either of these groups were found to exhibit contagious virus levels, which was comparable to 11.1% of those receiving a placebo.

The time to viral RNA clearance was decreased in participants who received the 800 mg dosage of molnupiravir as compared with those who had a placebo.

In terms of safety and tolerability, the drug was tied to few and mainly low-grade adverse effects. The incidence of treatment-related adverse events was lowest in the 800 mg group. The only adverse symptoms reported included headache, insomnia, and increased alanine aminotransferase levels.

The team concluded that in the Phase IIa clinical trial, molnupiravir was well tolerated and associated with potent antiviral efficacy. The researchers also reported reduced infection virus isolation and the time to elimination of SARS-CoV-2 RNA, as well as an increase in the number of participants who cleared viral RNA. Furthermore, molnupiravir was found to significantly reduce SARS-CoV-2 RNA levels from baseline as compared with those treated with a placebo.

“In conclusion, the results of this trial demonstrate the safety, tolerability, and antiviral efficacy of molnupiravir to reduce replication of SARS-CoV-2 and accelerate clearance of infectious virus and support ongoing trials of molnupiravir to prevent progression of COVID-19 and eliminate onward transmission of SARS-CoV-2.”

*Important Notice

medRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.


Source Link


DISCLAIMER

This blog is for information purposes only. The content is not intended as medical advice, diagnosis, or treatment. Should you have a medical or dermatological problem, please consult with your physician. None of the information or recommendations on this website should be interpreted as medical advice.

All product reviews, recommendations, and references are based on the author’s personal experience and impressions using the products. All views and opinions are the author’s own.

This blog post may contain affiliate links. An affiliate link means we may earn a commission if you click on a link and make a purchase, without any extra cost to you.

Please see our Disclaimer for more information.

DrAbout.Net

The leading source for trustworthy and timely health and medical news and information. Providing credible health information, supportive community, and educational services by blending award-winning expertise in content, community services, expert commentary, and medical review. Everything about health is here with the difference of Dr.About

Related Articles

Leave a Reply

Back to top button